摘要
Drug-eluting stent thrombosis has become a major safety concern after percutaneous coronary intervention （PCI） because of its close association with sudden death or ST-elevation myocardial infarction. The occurrence rate of stent thrombosis ranged from 0.6%-2.6% after selective PCI, and increased dramatically with premature cessation of antiplatelet treatment. Recent PCI guidelines generally recommend dual antiplatelet therapy with aspirin and clopidogrel for at least one year for all drug-eluting stent recipients at low risk of bleeding. However, whether dual antiplatelet therapy is sufficient for preventing late or very late stent thrombosis remains unclear. Here we reported a patient who suffered several episodes of drug-eluting stent thrombosis even on dual antiplatelet therapy.
Drug-eluting stent thrombosis has become a major safety concern after percutaneous coronary intervention （PCI） because of its close association with sudden death or ST-elevation myocardial infarction. The occurrence rate of stent thrombosis ranged from 0.6%-2.6% after selective PCI, and increased dramatically with premature cessation of antiplatelet treatment. Recent PCI guidelines generally recommend dual antiplatelet therapy with aspirin and clopidogrel for at least one year for all drug-eluting stent recipients at low risk of bleeding. However, whether dual antiplatelet therapy is sufficient for preventing late or very late stent thrombosis remains unclear. Here we reported a patient who suffered several episodes of drug-eluting stent thrombosis even on dual antiplatelet therapy.
